Inozyme Pharma (NASDAQ:INZY) Given “Buy” Rating at Needham & Company LLC
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $23.00 price target on the stock. Needham & Company LLC’s price target indicates a potential upside of […]
25 Oct 12:52 · The Markets Daily